rood blauwe elepsis logo Belegger.nl

Belgische aandelen Terug naar discussie overzicht

DBRS Confirms DEXIA Entities at A (high); Trend Revised to Stable from Negative

2 Posts
| Omlaag ↓
  1. [verwijderd] 10 december 2010 00:20
    Date of Release: 2010-12-08
    Dexia Group
    DBRS Confirms Dexia Entities at A (high); Trend Revised to Stable from Negative

    DBRS’s ratings for Dexia Group’s (Dexia or the Group) main operating entities – Dexia Crédit Local (Dexia CL), Dexia Bank Belgium (Dexia BB) and Dexia Banque Internationale à Luxembourg (Dexia BIL) – reflect their combined solid intrinsic credit strength. The support of the Belgian, French and Luxembourg states (collectively, the States) is factored into the final ratings. The long-term ratings of A (high), which were confirmed on 8 December 2010, reflect Dexia’s well-entrenched retail and commercial banking franchises in Belgium, Luxembourg and Turkey combined with its strong position in public finance. While still reducing the scope of its businesses, adjusting to the current funding environment and working down its legacy asset exposures, Dexia has remained profitable since its major losses in 2H08. The return to a Stable trend reflects the Group’s success in executing its Transformation Plan, its continued profitability and its improved liquidity profile, which limits the downward pressure on the ratings at this time.

    DBRS’s intrinsic assessment (IA) of “A” considers Dexia’s well-established and diversified franchise, underlying earnings resiliency, improved liquidity profile and strengthened capitalisation, but also recognises the challenges the Group faces given its wholesale funding reliance and the still disrupted financial markets. Ratings for Dexia’s principal subsidiaries reflect the combined strength of the Group, which operates these entities as integral components of its overall franchise and leverages their strengths for the benefit of the Group. Based on an SA-2 Support Assessment, Dexia’s Senior Long-Term Debt & Deposits rating of A (high) is one notch above the Group’s IA, reflecting the expectation of some timely form of systemic external support. DBRS views positively the support the Group has received from the States in terms of capital and debt guarantees that confirms DBRS’s expectation of systemic support.

    www.dbrs.com/research/236966?docId=23...
  2. [verwijderd] 10 december 2010 00:26
    16 november 2010 om 05u50
    Dirk Peeters (KBC Securities): “Kwartaalcijfers Dexia beter dan verwacht”
    Gerelateerd

    • Dynamiek bevestigd voor de commerciële metiers
    • Zonder rekening te houden met de meerwaarden op desinvesteringen stegen de opbrengsten uit de commerciële metiers met 5 % ten opzichte van 2T 2010
    • Stabiele kosten ten opzichte van 2T 2010, zonder de herstructureringskosten van 93 miljoen EUR geboekt in 3T 2010
    • Aanzienlijke daling van de kosten van risico: -61% tegenover 2T 2010
    •Aanzienlijke vooruitgang in het hervormingsplan
    • Behoefte aan kortermijnfunding: -23 miljard EUR ten opzichte van juni 2010 / -64 miljard EUR tegenover september 2009
    • Voor 25,7 miljard EUR aan obligaties en leningen verkocht tegen beperkte verliezen tegen eind oktober 2010
    Capaciteit om Tier 1 te genereren wordt bevestigd
    • Tier 1-ratio: 12,8 % (+59 bp tegenover juni 2010 / +100 bp tegenover september 2009)
    • Core Tier 1-ratio: 11,8 % (+55 bp tegenover juni 2010 / +99 bp tegenover september 2009)

    Dirk Peeters (KBC Securities): “De kwartaalcijfers van Dexia waren beter dan verwacht. Ik heb nog steeds een advies opbouwen en een koersdoel van 4,50 euro.”
2 Posts
|Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.011
AB InBev 2 5.495
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.466
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.569
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.710
Aedifica 3 902
Aegon 3.258 322.683
AFC Ajax 538 7.087
Affimed NV 2 6.289
ageas 5.844 109.887
Agfa-Gevaert 14 2.048
Ahold 3.538 74.328
Air France - KLM 1.025 35.018
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.036
Alfen 16 24.652
Allfunds Group 4 1.469
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 405
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.819
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.836 242.862
AMG 971 133.181
AMS 3 73
Amsterdam Commodities 305 6.687
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 489
Antonov 22.632 153.605
Aperam 92 14.965
Apollo Alternative Assets 1 17
Apple 5 381
Arcadis 252 8.763
Arcelor Mittal 2.033 320.638
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.288
Aroundtown SA 1 219
Arrowhead Research 5 9.727
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.087
ASML 1.766 106.337
ASR Nederland 21 4.452
ATAI Life Sciences 1 7
Atenor Group 1 484
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.647
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.392